drugset / Trial / NCT02965664

Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects

NCT02965664 ↗

Phase 2 Completed 36 enrolled Orasis Pharmaceuticals Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to Establish Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects.

Timeline

Start
2016-12
Primary completion
2017-04
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CILMOSTIM Protein / enzyme biologic — Topical

Indications